Phase 1a/b study: positive placebo-controlled safety data for KL1333 and the first evidence of efficacy 

Important events second quarter (Apr - Jun 2021)

• Data from the Phase 1a/b clinical study of KL1333 was released and confirmed the safety and pharmacokinetic profile of the drug. In addition, in a cohort of eight patients (six dosed with KL1333, two with placebo), there were signs of efficacy across well-established relevant clinical endpoints including two patient-reported fatigue endpoints and a functional endpoint.
• Extraordinary General Meeting was held on 29 April 2021. 
• The directed share issue, approved by the Extraordinary General Meeting, was completed. The Company raised approx. SEK 76 million after deduction of issue costs.
• Annual General Meeting was held on 20 May 2021.

Important events after the reporting period

• The validation study of fatigue as an endpoint, for the KL1333 Phase 2/3 study, was completed.

Financial information

April-June 2021*

• Net revenues: SEK 18,000 (97,000)
• Other operating income: SEK 0,000 (34,000) 
• Loss before tax: SEK 30,314,000 (20,312,000) 
• Loss per share: SEK 0.08 (0.09)
• Diluted loss per share: SEK 0.08 (0.09) 

January-June 2021*

• Net revenues: SEK 18,000 (105,000)
• Other operating income: SEK 0,000 (34,000) 
• Loss before tax: SEK 51,770,000 (36,849,000) 
• Loss per share: SEK 0.13 (0.18)
• Diluted loss per share: SEK 0.13 (0.18)

* APM Alternative perfomance measures, see definition on page 20.

The complete Interim report is available for download below and through the company's website www.abliva.com